Registered number
14269943
Eveready Pharma Ltd
Filleted Accounts
31 December 2025
Eveready Pharma Ltd
Registered number: 14269943
Balance Sheet
as at 31 December 2025
Notes 2025 2024
£ £
Fixed assets
Intangible assets 3 1,439,642 624,376
Tangible assets 4 276,140 162,864
1,715,782 787,240
Current assets
Stocks 101,250 41,250
Debtors 5 848,577 190,916
Cash at bank and in hand 241,659 302,686
1,191,486 534,852
Creditors: amounts falling due within one year 6 (890,890) (394,461)
Net current assets 300,596 140,391
Total assets less current liabilities 2,016,378 927,631
Creditors: amounts falling due after more than one year 7 (1,444,575) (743,328)
Net assets 571,803 184,303
Capital and reserves
Called up share capital 2 2
Profit and loss account 571,801 184,301
Shareholders' funds 571,803 184,303
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Mr Rachinder Singh Judge
Director
Approved by the board on 23 July 2026
Eveready Pharma Ltd
Notes to the Accounts
for the year ended 31 December 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 5 years
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Leased assets
A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2025 2024
Number Number
Average number of persons employed by the company 18 4
3 Intangible fixed assets £
Goodwill:
Cost
At 1 January 2025 657,238
Additions 892,324
At 31 December 2025 1,549,562
Amortisation
At 1 January 2025 32,862
Provided during the year 77,058
At 31 December 2025 109,920
Net book value
At 31 December 2025 1,439,642
At 31 December 2024 624,376
Goodwill is being written off in equal annual instalments over its estimated economic life .
4 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2025 203,580
Additions 192,490
At 31 December 2025 396,070
Depreciation
At 1 January 2025 40,716
Charge for the year 79,214
At 31 December 2025 119,930
Net book value
At 31 December 2025 276,140
At 31 December 2024 162,864
5 Debtors 2025 2024
£ £
Trade debtors 355,019 123,814
Vat Recoverable 81,585 10,969
Other debtors 411,973 56,133
848,577 190,916
6 Creditors: amounts falling due within one year 2025 2024
£ £
Bank loans and overdrafts 110,137 -
Trade creditors 521,735 184,500
Director's Account 41,835 71,666
Taxation and social security costs 139,462 27,761
Other creditors 77,721 110,534
890,890 394,461
7 Creditors: amounts falling due after one year 2025 2024
£ £
Bank loans 701,630 -
Other creditors 742,945 743,328
1,444,575 743,328
8 Related party transactions
Other creditors due after one year includes the amount of £ 242,945 (2024: £243,328) due to RSJ Pharma Ltd. Mr R S Judge is a Director of the company and holds a material interest. There are no terms as to interest or repayment in respect of this amount.
9 Other information
Eveready Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
Magnolia House
Spring Villa Park
11 Spring Villa Road
Edgware
HA8 7EB
Eveready Pharma Ltd 14269943 false 2025-01-01 2025-12-31 2025-12-31 VT Final Accounts May 2026 Mr Rachinder Singh Judge No description of principal activity 14269943 2024-01-01 2024-12-31 14269943 core:WithinOneYear 2024-12-31 14269943 core:AfterOneYear 2024-12-31 14269943 core:ShareCapital 2024-12-31 14269943 core:RetainedEarningsAccumulatedLosses 2024-12-31 14269943 2025-01-01 2025-12-31 14269943 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 14269943 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 14269943 bus:Director40 2025-01-01 2025-12-31 14269943 1 2025-01-01 2025-12-31 14269943 2 2025-01-01 2025-12-31 14269943 core:Goodwill 2025-01-01 2025-12-31 14269943 core:PlantMachinery 2025-01-01 2025-12-31 14269943 countries:England 2025-01-01 2025-12-31 14269943 bus:FRS102 2025-01-01 2025-12-31 14269943 bus:FilletedAccounts 2025-01-01 2025-12-31 14269943 2025-12-31 14269943 core:WithinOneYear 2025-12-31 14269943 core:AfterOneYear 2025-12-31 14269943 core:ShareCapital 2025-12-31 14269943 core:RetainedEarningsAccumulatedLosses 2025-12-31 14269943 core:Goodwill 2025-12-31 14269943 core:PlantMachinery 2025-12-31 14269943 2024-12-31 14269943 core:Goodwill 2024-12-31 14269943 core:PlantMachinery 2024-12-31 iso4217:GBP xbrli:pure